Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant

Table 5 Appearance of adverse events in dependence on the course of therapy n (%)

	Moderate side effects		Severe side effects
	TW 1-12	TW 13-48	TW 1-12	TW 13-48
Hematological toxicity	0	0	0	0
Anemia	≤ 10 g/dL	≤ 10 g/dL	≤ 8 g/dL	≤ 8 g/dL
	9 (47.4)	11 (57.9)	8 (42.1)	2 (10.5)
Low WBC (< 1/μL)	< 3.4/μL	< 3.4/μL	< 1/μL	< 1/μL
	16 (84.2)	14 (73.7)	2 (10.5)	3 (15.8)
Low PT (< 50/μL )	< 50/μL	< 50/μL	< 20/μL	< 20/μL
	3 (15.7)	6 (31.6)	0	0
Renal failure	8 (42.1)	0	1 (5.2)	0
Dermatological toxicity	0	0	0	0
Rash std. I	7 (36.8)	0	0	0
Rash std. II	0	0	1 (5.2)	0
Rash std. III	0	0	0	0
Anorectal pain	9 (47.4)	0	10 (52.6)	0
Pruritus	4 (21.0)	0	4 (21.0)	0
Stomatitis	3 (15.7)	0	1 (5.2)	0
Loss of appetite	5 (26.3)	0	0	0
Loss off weight > 10%	6 (31.6)	0	1 (5.2)	0
Diarrhoe	5 (26.3)	0	1 (5.2)	0
Weakness	10 (52.6)	7 (36.8)	0	0
Hospitalisation	0	0	3 (10.5)	2 (15.8 )
Hepatic decompensation	0	0	1 (5.2)	0
Edema	0	0	3 (15.8)	0
Diabetes melitus	0	0	3 (15.8)	3 (15.8)
Psychiatric disorders	0	4 (21.0)	0	1 (5.2)
Medical induced fever	0	9 (47.4)	0	0
Infection	0	0	0	2 (10.5)

WBC: White blood count; TW: Treatment week; PT: Platelets.